Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug duo aims to slash leukemia relapse after bone marrow transplant

NCT ID NCT07101588

Recruiting now Disease control Sponsor: Chinese PLA General Hospital Source: ClinicalTrials.gov ↗

First seen Mar 20, 2026 · Last updated May 13, 2026 · Updated 8 times

Summary

This study tests whether adding two drugs (ruxolitinib and decitabine) to the standard chemotherapy given before a stem cell transplant can lower the chance of leukemia returning in high-risk patients. About 200 adults and teens with acute myeloid leukemia in first remission will be randomly assigned to receive either the enhanced or standard pre-transplant regimen. The main goal is to see if the new combo improves survival without relapse or severe graft-versus-host disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Chinese PLA General Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100853, China

    Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)